Analysis
OrbiMed has closed two new funds totaling more than $3 billion aimed at healthcare and life sciences, the firm announced:
- OrbiMed Private Investments X — over $1.9 billion for life sciences venture capital in the US and Europe.
- OrbiMed Asia Partners VI — more than $1 billion for healthcare growth equity and venture capital across Asia.
Managing Partners Carl Gordon and Carter Neild said AI in drug development, new treatment modalities, and China's expanding biotech sector are widening the opportunity set, with Gordon calling it "the most exciting time to invest in life sciences innovation."
“- OrbiMed Private Investments X — over $1.9 billion for life sciences venture capital in the US and Europe.”
OrbiMed is one of the largest dedicated healthcare investors in the world, running 20 partners and more than 150 investment professionals out of 12 offices, with a platform spanning private equity, public equity, and royalty and credit strategies. The new funds bring total assets under management past $21 billion, money the firm plans to deploy from early-stage biopharma and medical devices through later-stage, tech-enabled healthcare services.
Who Else Is Writing Healthcare VC's Biggest Checks?
OrbiMed competes with a small set of healthcare-dedicated investors writing checks at this scale: RA Capital Management, Flagship Pioneering, Perceptive Advisors, and the trio of Bain Capital Life Sciences, Forbion and Novo Holdings, which just co-led OMass Therapeutics' $310 million Series C for its rare-disease GPCR program. That round, alongside this week's run of biotech IPOs, suggests healthcare-specific capital is still finding targets even as generalist VCs have pulled back from the sector since 2022.
OrbiMed hasn't disclosed the size of its prior flagship vehicles, so there's no clean before-and-after comparison for this specific fund family. What's measurable is the mismatch between committed capital and realized returns: a $3 billion close is a signal of LP demand for healthcare exposure, not proof that OrbiMed's existing portfolio has already returned capital at a rate that justifies doubling down. Biotech fundraising broadly has been uneven since 2022, and a fresh pool of dry powder doesn't guarantee deployment will outperform the vintage years that preceded this one.
The nearer-term test is whether OrbiMed's stated China thesis holds up alongside the broader US-China tech friction playing out elsewhere this week, from chip export controls to data-center supply chains. Healthcare and semiconductors sit in different regulatory lanes, but a fund explicitly sized for Asian healthcare growth equity is making a multi-year bet that cross-border capital flows into Chinese biotech stay open.
